$0.37
Today
as of Sep 4, 16:54 ET
Last 30 days
Recent Press Releases & News
SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
Scienture Holdings: Q2 Earnings Snapshot
SCIENTURE Launches REZENOPY as Second FDA-Approved Commercial Product
Overview
52-week range
$0.24
$2.60
6% of range
Avg surprise (last 0)
—
Avg reaction (last 2)
+0.1%
50% positive
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.07 | — | — | — | — | financials |
| Fri May 15, 2026 | Mar/2026 | $-0.08 | — | — | +75.8% | -1.9% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.19 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.48 | — | — | — | — | earnings |
| Mon May 12, 2025 | Mar/2025 | $-0.33 | — | — | — | +2.2% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-1.34 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.30 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $16.77 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-4.57 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-2.90 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-1.01 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $343,639 | $56,325 | — | $590,050 | — | $10,258 | — | $64,861 |
| Cost of revenue | $7,860 | $2,475 | — | $15,429 | — | $9,585 | — | $60,978 |
| Gross profit | $335,779 | $53,850 | — | $574,621 | — | $673 | — | $3,883 |
| Operating income | $-3M | $-4M | — | $-4M | $-5M | $-4M | — | $-3M |
| Net income | $-3M | $-3M | — | $-4M | $-7M | $-3M | — | $-3M |
| EPS (diluted) | $-0.07 | $-0.08 | — | $-0.19 | $-0.48 | $-0.33 | — | $-1.34 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $8M | $4M | $7M | $355,692 | $15,391 | $2M | — | $579,103 |
| Inventory | $203,074 | $210,934 | $213,408 | $234,521 | — | — | — | $7,884 |
| Total current assets | $9M | $5M | $8M | $1M | $856,625 | $8M | $6M | $7M |
| Total assets | $88M | $81M | $84M | $105M | $84M | $84M | $105M | $94M |
| Long-term debt | — | — | — | $2M | $4M | $3M | $3M | — |
| Total liabilities | $24M | $14M | $14M | $22M | $26M | $25M | $26M | $9M |
| Total equity | $64M | $67M | $70M | $83M | $78M | $81M | $79M | $85M |
Implied volatility — last 90 days
No IV snapshots yet for SCNX.
IV is captured twice daily (9:15 AM & 4:30 PM ET) for tickers with upcoming earnings. Comes online automatically once the next options refresh runs.